Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142605 | 0.93 | KDM4E (0.45) | SETD7KDM4ENPC1RAB9AKCNH2 | |
| SCHEMBL3138906 | 0.91 | ROCK2 (0.45) | SETD7KDM4ENPC1RAB9AKCNH2 | |
| SCHEMBL3138857 | 0.84 | SETD7 (0.53) | SETD7KCNH2 | |
| SCHEMBL3138213 | 0.82 | MAPK1 (0.46) | SETD7KDM4EKCNH2 | |
| SCHEMBL490493 | 0.81 | ROCK2 (0.48) | SETD7KCNH2ALDH1A1 | |
| SCHEMBL3030798 | 0.81 | TP53 (0.60) | KDM4ETP53GLATHRBALDH1A1 | |
| SCHEMBL3134805 | 0.80 | SETD7 (0.47) | SETD7KDM4ENPC1RAB9AKCNH2 | |
| SCHEMBL3030801 | 0.79 | SETD7 (0.41) | SETD7KDM4EKCNH2TP53GLA | |
| SCHEMBL3132994 | 0.78 | SETD7 (0.45) | SETD7KDM4EKCNH2GLAALDH1A1 | |
| SCHEMBL3131638 | 0.76 | SETD7 (0.51) | SETD7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2067777-B1 | OXEPIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8222419-B2 | Oxepin derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100004456-A1 | Oxepin derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2067777-A1 | OXEPIN DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004456-A1 | Oxepin derivative | HRH4, HRH3, HCRTR2 | SETD7 2087/4885KDM4E 1720/4885NPC1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.